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Background: We investigated the clinical implications of KRAS and BRAF mutations detected in both archival tumor tissue and
plasma cell-free DNA in metastatic colorectal cancer patients treated with irinotecan monotherapy.
Methods: Two hundred and eleven patients receiving second-line irinotecan (350mgm 2 q3w) were included in two
independent cohorts. Plasma was obtained from pretreatment EDTA blood-samples. Mutations were detected in archival tumour
and plasma with qPCR methods.
Results: Mutation status in tumor did not correlate to efficacy in either cohort, whereas none of the patients with mutations
detectable in plasma responded to therapy. Response rate and disease control rate in plasma KRAS wt patients were 19 and 66%
compared with 0 and 37%, in patients with pKRAS mutations, (P¼ 0.04 and 0.01). Tumor KRAS status was not associated with PFS
but with OS in the validation cohort. Plasma BRAF and KRAS demonstrated a strong influence on both PFS and OS. The median
OS was 13.0 mo in pKRAS wt patients and 7.8 in pKRAS-mutated, (HR¼ 2.26, Po0.0001). PFS was 4.6 and 2.7 mo, respectively
(HR¼ 1,69, P¼ 0.01). Multivariate analysis confirmed the independent prognostic value of pKRAS status but not KRAS tumor
status.
Conclusion: Tumor KRAS has minor clinical impact, whereas plasma KRAS status seems to hold important predictive and
prognostic information.
Worldwide, colorectal cancer (CRC) remains a significant cause of
cancer morbidity and mortality, with an overall incidence of
416 000 new cases per year in the Nordic countries (Ferlay et al,
2010). Unfortunately, the majority of the patients will eventually
develop metastatic disease, and despite the availability of several
effective cytotoxic drugs and new biological agents, the prognosis
remains poor and the curative options for metastatic disease
limited.
The cornerstone in the treatment of mCRC has been
fluoropyrimidines and related pro-drugs for more than four
decades. 5-Fluorouracil alone has increased the OS beyond 6
months (Prescrire, no authors listed, Chemotherapy of metastatic
colorectal cancer, 2010; Jemal et al, 2011). The introduction of
oxaliplatin- and irinotecan-based combination therapies has
improved OS even further, whereas the addition of biological
agents targeting the EGFR system and the anti-angiogenetic drug
avastin eventually has led to median OS results beyond 2 years
(Cunningham et al, 2004; Prescrire, no authors listed, Chemotherapy
of metastatic colorectal cancer, 2010; Jemal et al, 2011). Consequently,
the majority of patients will be offered several lines of palliative
chemotherapy, with an accompanying risk of substantial side
effects. Careful selection of patients and monitoring during therapy
are therefore essential.
Irinotecan is a widely used semisynthetic analogue of camp-
tothecin, a naturally occurring quinolone alkaloid targeting the
topoisomerase I, which is responsible for maintaining the
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functional compact and supercoiled DNA double-helix structure.
Thus, Irinotecan generates single-stranded DNA breaks, which can
lead to overall DNA damage and thereby cell death. Efficacy of
irinotecan in mCRC was demonstrated more than a decade ago;
response rates from monotherapy have been recorded to B14%,
with an overall benefit of PFS and OS in the second-line setting.
The major dose-limiting toxicities include diarrhoea and myelo-
suppression, rendering a strong need for predictive and prognostic
markers to optimise patient treatment.
In mCRC, a major proportion of tumors harbour KRAS or
BRAF mutations, which are negative predictors of outcome from
EGFR-targeted therapies, predominantly in third-line settings of
combination therapy with irinotecan (Qui et al, 2010; Adelstein
et al, 2011). Tumour mutation status does not seem to affect
outcome from chemotherapy alone; however, its role has been only
sparsely investigated. However, archival tumour tissue obtained
several years earlier and prior to multiple lines of therapy
previously may not sufficiently reflect disease biology at the time
of therapy. Addressing of this by repeated biopsies is not applicable
because of both ethical and practical reasons.
Recently, we and others have shown that small fragments of free
DNA measured in the plasma from cancer patients is a feasible
source for mutation detection and quantification in the peripheral
blood (Spindler et al, 2012; Murtaza et al, 2013). We have used a
feasible in-house qPCR method to detect KRAS and BRAF
mutations in the plasma from patients with mCRC treated with
irinotecan and cetuximab and shown a clear correlation with
outcome from plasma analysis (Spindler et al, 2012).
The present study aimed at investigating the predictive and
prognostic value of KRAS and BRAF mutations in tumour and
plasma from patients treated with irinotecan monotherapy.
MATERIALS AND METHODS
The study included a retrospective test cohort and a cohort of
patients included in a prospective biomarker study for validation,
in total comprising 211 mCRC patients treated with irinotecan at
the Department of Oncology, Vejle Hospital, Denmark.
Retrospective cohort. Irinotecan monotherapy is the standard
second-line therapy for mCRC in our department, and KRAS and
BRAF mutation analysis is routinely performed prior to potential
third-line therapy with irinotecan- and EGFR-targeted therapy.
Mutational status in archival tumour tissue and clinical data was
collected for the retrospective analysis from 111 consecutively
treated patients receiving at least one cycle of irinotecan
monotherapy. The majority of patients had also participated in a
prospective third-line biomarker study. The purpose of this study
was to investigate the predictive and prognostic value of tumour
mutation status in regard to irinotecan monotherapy. Patients were
treated with intravenous irinotecan monotherapy 350mgm 2
q3w and supportive care according to the local guidelines.
Computed tomography scans of the chest and abdomen were
performed every 9 weeks.
Prospective biomarker study. Patients who were candidates for
irinotecan monotherapy were included in a prospective non-
randomised phase II and biomarker study (Protocol ID
S-20090114). Inclusion criteria were as follows: histopathologically
verified metastatic colorectal cancer, measurable disease according
to RECIST version 1.1, indication for irinotecan monotherapy
according to local guidelines, informed consent to therapy and
biobank collection and age X18 years. Patients with other
concurrent cancer diseases (within 5 years of inclusion, apart
from squamous cell carcinoma of the skin), having received
experimental therapyo30 days prior to inclusion, or with planned
radiotherapy to target lesions were not eligible. Patients were
treated with intravenous irinotecan monotherapy 350mgm 2
q3w and supportive care according to the local guidelines.
Response evaluations with CT scans of the chest and abdomen
were performed every 9 cycles according to RECIST v 1.1.
All patients provided signed informed consent before study
entry and the ethics committee (The Regional Scientific Ethical
Committee for Southern Denmark) approved the studies prior to
commencement.
Specimen characteristics. Archival formalin-fixed, paraffin-
embedded tumour tissue was used for tumour mutation detection.
After informed consent, pretreatment blood samples were drawn
prior to the first cycle of therapy and at each visit until the time of
progression. Plasma was obtained from blood samples collected in
EDTA tubes and centrifuged at 2000 g for 10min within 2 h of
collection, before being stored at  80 1C until use. All samples
were analysed, blinded to the study end points.
DNA purification. DNA was extracted from formalin-fixed
paraffin-embedded tissue using QIAamp DNA Mini Kit (Qiagen,
Hilden, Germany) after histological confirmation of viable tumour
cells on HE-stained slides. DNA was purified from 1ml of plasma
using a QIAsymphony virus/bacteria midi-kit on a QIAsymphony
robot (Qiagen), according to the manufacturer’s instructions. DNA
was eluted in 110 ml.
KRAS and BRAF mutation detection. The KRAS analysis of
archival tumour tissue was performed with the DxS kit
(Garm Spindler et al, 2009) and validated in-house assays as also
previously described (Garm Spindler et al, 2009; Spindler et al,
2012). Analyses of plasma DNA were performed with the in-house
assays that are based on the Amplification Refractory Mutation
System-Quantitative PCR (ARMS-qPCR) methodology. The assays
detect six mutations in KRAS codon 12 (Gly12Ala, Gly12Arg,
Gly12Asp, Gly12Cys, Gly12Ser and Gly12Val), one mutation in
KRAS codon 13 (Gly13Asp) and one BRAF codon 600 mutation
(Val600Glu).
Statistical analysis. Data are presented according to the REMARK
guidelines. Correlation between variables and mutation status were
analysed with cross tabulations. The Kaplan–Meier method was
applied to estimate PFS and OS, and differences in outcome
between subgroups were compared using the log-rank test.
A multivariate Cox regression analysis was performed to examine
the association of tumour and plasma mutation status with overall
and disease-free survival, whereas controlling for effects of age and
PS. P-values referred to two-tailed tests and were considered
significant when Pp0.05. Statistical analyses were carried out
using the NCSS statistical software 2007 v.07.1.5 (NCSS Statistical
Software, Kaysville, UT, USA, www.ncss.com).
RESULTS
Patients. Baseline characteristics from the two cohorts are
presented in Table 1, which also shows the number of samples
available for the biomarker analyses. The baseline characteristics
were similar in the two cohorts.
Retrospective data. One hundred and eleven patients were
evaluated; the analysis included 48 female and 68 male patients,
with a median age of 62 years. The median number of cycles
received was six (range 2–15). The median progression-free and
overall survivals were 4.9 months (95% CI 4.3–6.1 months) and
16.1 months (95% 13.7–18.2 months), respectively. Response
evaluation according to RECIST revealed a partial response rate of
14% and SD in 50% of patients, with a subsequent disease control
rate of 64%, in agreement with the literature. Thirty-six (32%)
patients progressed after the first evaluation.
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Prospective study. All but one patient commenced therapy as
planned and the median number of cycles received was four (range
1–15). One patient withdrew consent for data analysis and blood
sampling and is included in the ITT population; however, baseline
characteristics and outcome parameters were consequently not
recorded. The overall toxicity was comparable to the literature,
with 41% who experienced diarrhoea and 21% neutropaenia.
Response evaluation was not available for 13 patients but the
overall response rate was 13%, whereas 57% obtained disease
control and 43% progressed before or at first response evaluation.
At the time of analysis, the median observation time was 9.5
month, with 90 patients dead and 9 still alive. The median PFS was
4.6 mo (95% CI 3.7–5.8) and the median OS 9.5 mo (95% CI 8.4–
11.8) in the ITT cohort.
Mutations and relation to demographic characteristics. In the
retrospective cohort, tumour DNA was available for the KRAS
analysis in 109 (99%) of the patients and included 42 (39%)
patients with mutations and 67 (60%) wild type (wt) (that is,
absence of mutations). Eight patients had a BRAF V600 mutation
(7%). Mutational status was not associated with baseline patient
characteristics (data not shown). Data from the prospective
biomarker study showed similarly that KRAS mutations were
detected in 44 (45%) tumours and BRAF mutations in 8 (8%), with
no association to baseline characteristics.
KRAS and BRAF mutation detection in plasma and tumour.
Ninety-seven patients had available tumour and plasma samples
for mutation analysis, respectively; however, only 95 patients had
matching tumour and blood samples available for comparison of
mutation status. In these, KRAS mutations were detected in 44
tumours and BRAF mutations in 7 tumours. The overall
concordance between tumour and plasma KRAS status was high.
Fifty patients had wt tumour and corresponding plasma KRAS
status, whereas 28 had detectable mutations in both. In 16 patients
with wt plasma sample, a previous mutations in the tumour had
been detected, whereas only one patient had a detectable plasma
KRAS mutation not previously found in the tumour. For BRAF
status, the agreement was complete¼ 100% (but one patient with a
BRAF-positive tumour sample did not have a matching plasma
sample).
The predictive value of KRAS mutations in tumour. Retro-
spective analysis revealed no correlation between mutation status
in tumour and outcome in terms of tumour response, disease
control rates or progression rates according to the KRAS tumour
status as demonstrated in Table 2. This was confirmed in the
prospective study.
The predictive value of KRAS mutations in plasma. Interes-
tingly, in the prospective study, none of the patients with KRAS
mutations detectable in plasma responded to therapy (RR¼ 0),
whereas the RR in pKRAS wt patients was 19%, (P¼ 0.014). The
disease control rate in pKRAS wt patients was 66% compared with
37% in the patients with pKRAS mutations (P¼ 0.01). These
differences were highly significant, indicating a predictive value of
KRAS when detectable in the plasma (Table 2).
The prognostic value of KRAS detection in tumour in test and
validation cohorts. The KRAS tumour mutation status did not
significantly influence PFS or overall survival after second-line
irinotecan therapy in the retrospective evaluation (Table 2). In the
prospectively investigated cohort, KRAS tumour mutation status
was significantly associated with OS but not with PFS, as shown
from Table 2 and Figure 1.
Table 1. Patient characteristics
Colorectal cancer cohorts
Characteristics Retrospective n¼111 Prospective n¼100
Age (median/range) 62 (26-80) 66 (37-83)
Gender
Female 48 (43) 34 (34)
Male 63 (57) 65 (65)
PS
0 61 (55) 45 (45)
1 47 (42) 46 (46)
2 3 (3) 8 (8)
Tumor KRAS 109 97
Mutation 42 (39) 44 (45)
Wild type 67 (60) 53 (55)
Plasma KRAS NA 97
Mutations 30 (31)
Wild type 67 (69)
Tumour BRAF 109 97
Mutation 8 (7) 8 (8)
Wild type 101 (93) 89 (92)
Plasma BRAF NA 97
Mutation 7 (7)
Wild type 90 (93)
Table 2. Univariate analysis of outcome parameters according to KRAS and BRAF mutations
Response PFS OS
Marker Cohort RR P DCR P HR 95% CI P HR 95% CI P
KRAS tumour wt/m R 15/12 40.05 73/60 40.05 1.08 0.68–1.71 40.05 1.33 0.89–1.97 40.05
BRAF tumour wt/m R 15/0 40.05 68/63 40.05 0.56 0.22–1.42 40.05 0.95 0.40–2.23 40.05
KRAS tumour wt/m P 17/8 40.05 62/53 40.05 0.84 0.56–1.26 40.05 0.61 0.40–0.95 0.02
BRAF tumour wt/m P 14/0 40.05 62/14 0.02 0.28 0.08–1.01 0.0001 0.30 0.09–1.04 0.0005
KRAS plasma wt/m P 19/0 0.01 66/37 0.01 0.59 0.36–0.97 0.01 0.44 0.26–0.76 0.0002
BRAF plasma wt/m P 14/0 40.05 60/17 0.04 0.29 0.08–1.13 0.0006 0.34 0.09–1.19 0.003
Abbreviations: CI¼ confidence interval; DCR¼disease control rate in per cent; HR¼ hazard ratio; m¼mutation; OS¼overall survival; P¼prospective cohort; p¼P-value; PFS¼progression-
free survival; RR¼ response rate in per cent; R¼ retrospective cohort; wt¼wild type.
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The prognostic value of KRAS detection in plasma. A clearly
enhanced prognostic value of plasma mutations compared with
tumour mutations was revealed when analysing the relationships
between OR and DFS and the plasma KRAS mutation status
(Table 2 and Figure 1). The median OS was 13.0 months (95% CI
9.5–15.1) in plasma KRAS wt patients and 7.8 months (4.6–8.4) in
patients with plasma KRAS mutations, HR 2.26 (95% CI 1.31–
3.90), Po0.0001. The median PFS were 4.6 months (95% CI 3.3–
6.4) and 2.7 months (95% CI 2.1–4.5), respectively, HR 1.69 (95%
CI 1.03–2.77), P¼ 0.01.
BRAF mutations in tumour and plasma. The number of BRAF
mutations was small (n¼ 7(8)), and conclusions drawn from this
sample size should therefore be regarded with caution. Data
revealed – similarly to the results for KRAS – that none of the
patients with detectable BRAF mutations in the plasma responded
to therapy and, although these differences did not reach
significance, they translated into differences in DCR, PFS and OS
(Table 2 and Figure 1).
Multivariate survival analysis. The Cox multivariate regression
analysis is presented in Table 3. The model included age (4/o66
years), PS and mutation status in tumour and plasma. The model
confirmed an independent prognostic value of plasma KRAS
status, whereas the effect of tumour KRAS status seemed to
diminish.
DISCUSSION
KRAS is the most commonly mutated gene in colorectal cancer
and is regarded as an early event in carcinogenesis (Andreyev et al,
2001). The constitutive activation of KRAS as well as BRAF
mutations leads to EGFR-independent downstream signalling and
hereby tumorigeneity in metastatic colorectal cancer, which drives
tumour growth and progression and impairs response to EGFR
inhibition. The prognostic relevance of these downstream
mutations in CRC has been investigated for decades with
inconsistent results but has attracted increasing focus lately as a
consequence of the collection of prospective clinical data and
availability of mutation status in larger cohorts.
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Figure 1. Kaplan–Meier estimates of survival among patients with KRAS or BRAF mutations detected in archival tumour tissue (A) and in plasma (B)
in the prospective cohort.
Table 3. Multivariate Cox regression analysis
PFS OS
Variables
Hazard ratio
(95% CI) P-value
Hazard Ratio
(95% CI) P-value
PSa,b 1.2
(0.8–1.8)
0.35 1.9
(1.3–2.8)
0.001
Age
o Medianc
4 Median
0.6
(0.4–1.0)
0.03 0.8 (0.5–1.2) 0.22
Tumour KRAS status
Wild typec
Mutation
1.0
(0.6–1.7)
0.92 1.2
(0.7–2.3)
0.52
Plasma KRAS status
Wild typec
Mutation
1.9
(1.1–3.5)
0.03 2.7
(1.4–5.2)
0.004
Plasma (and tumour) BRAF status
Wild typec
Mutation
5.3
(2.1–13.0)
0.0002 4.3
(1.7–10.6)
0.002
The Hazard ratio refers to moving from the reference group to the other group or changing
one step in parameters entered as continuous variables.
aPS¼Performance Status (ECOG).
bEntered as a continuous variable.
cReference group.
BRITISH JOURNAL OF CANCER pKRAS in metastatic colorectal cancer
3070 www.bjcancer.com |DOI:10.1038/bjc.2013.633
Although the majority of studies have indicated a worse prognosis
in patients with KRAS-mutated CRC, a large number of investiga-
tions have failed to demonstrate an association between the
mutations and outcome, as discussed recently by Yokota (2012)
and Phipps et al (2013). The Rascal study demonstrated a clear
prognostic impact of KRAS (Andreyev et al, 2001); however,
translational research data from the PETCAC-3, EORTC 40993
and SAKK 60-00 trials failed to demonstrate a relevant prognostic
impact (Roth et al, 2010). A very recent retrospective study of two
major Scandinavian cohorts have also shown inconsistent results,
BRAF being the only prognostic factor in the first study, whereas
KRAS had a strong prognostic impact in the second (Eklo¨f et al.,
2013). Such inconsistencies between studies have been attributed to
the differences in patient selection, sample sizes, methods used and
lack of control for other relevant prognostic markers such as BRAF,
MSI and PTEN expression. Furthermore, a recent population-based
study from theWestern Washington State of 1989 patients diagnosed
with CRC revealed an overall association with disease-specific
survival but not in patients who presented with distant-stage disease
(Phipps et al, 2013). It has consequently also been suggested that the
prognostic role of KRAS may differ by stage of the disease.
Regarding the predictive value, testing for KRAS mutations in
late-stage disease prior to anti-EGFR-targeted treatment has been
implemented in clinical practice as a consequence of the overall
consistent results in this setting; however, the role of KRAS
mutations as biomarker for outcome of similar combination
regimens in the first-line settings is less clear. Two large phase III
studies failed to demonstrate a PFS or OS improvement from the
addition of cetuximab to oxaliplatin-based first-line combination
therapy (Maughan et al, 2011; Tveit et al, 2012). Interestingly, these
trials even seemed to suggest a detrimental effect of the EGFR
inhibition in patients with KRAS mutations; however, no clear
explanation for this potential negative interaction has been
revealed. Similar data were found in the randomised PRIME
study, investigating the addition of panitumumab to oxaliplatin
also in the first-line setting (Douillard et al, 2010). Curiously, a
single recent evaluation has shown a possible predictive value of
KRAS mutations for outcoming of oxaliplatin-based first- and
second-line therapies, with a significantly higher RR and longer
PFS in patients with KRAS-mutant disease compared with KRAS
wt patients, primarily in the first-line setting (Basso et al, 2013);
however, the sample size was small and results should be validated.
The present study supplements the current knowledge in two
major aspects; firstly, it addresses the possible predictive and
prognostic value of KRAS and BRAF in the second-line setting of
irinotecan monotherapy as opposed to combination with anti-
EGFR antibodies; secondly, it examines the value of measuring
the mutations in the more timely pretreatment plasma sample.
The role of mutation status in the archival tumour tissue was first
investigated in a test cohort and validated in a prospectively
collected study. Results showed that KRAS mutations detected in
the archival tumour tissue were not predictive for response and we
were unable to reveal a prognostic value of KRAS in archival tissue.
In contrast, we found a strong independent prognostic value of the
plasma analysis. Furthermore, patients with detectable KRAS
mutations in the plasma had a poor chance of tumour response to
therapy. In line with the data from third-line combinations of
irinotecan with anti-EGFR antibodies, none of the patients with
KRAS-mutated disease achieved an objective response, resulting in
statistically significant differences.
The frequency of BRAF in both cohorts was low, resulting in
broad confidence intervals, which indicate that results should be
interpreted with caution. However, data suggested a confirmation
of the poor prognosis in patients with BRAF-mutant disease
(Ogino et al, 2012).
This study presents new evidence, which at least partially may
explain the diverging and contradictive results with respect to the
clinical importance of KRAS mutations. Intratumoral heterogene-
ity as well as heterogeneity among tumour and metastases exist and
could have clinical implications. Another problem is ‘heterogene-
rity’ over time. Clonal selection – especially provoked by treatment
– may well result in major quantitative differences in the ratio
between mutated and wt cells. This aspect has never been
addressed. Taken together, it may well be hypothesised that
tumour tissue is not the relevant starting material and the liquid
biopsy represented by a blood sample should be the material of
choice.
The obvious limitations of a small sample size and non-
randomised design should be acknowledged and any conclusions
on the predictive value of mutations detected in the plasma should
therefore be regarded with caution. However, this study indicates
that timely molecular characterisation of the disease is important
and that plasma KRAS mutation status holds important predictive
and prognostic information regarding the outcome of irinotecan
monotherapy in mCRC, whereas the use of archival tumour tissue
seems insufficient. These findings are hypothesis-generating but
novel and call for validation in a randomised trial.
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